Clinical

Dataset Information

0

Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer


ABSTRACT: The AMALTHEA (Aflibercept MAintenance after first-Line THErapy with FOLFIRI+Aflibercept in metastatic colorectal cancer patients) trial is an investigator-initiated, single arm, open-label, phase II study. Patients with histologically proven metastatic colorectal carcinoma will be treated with a combination of FOLFIRI and aflibercept for 6 months. Both Kirsten rat sarcoma viral oncogene homolog (KRAS) wild type (wt) and mutant (mut) patients wil be enrolled. In the absence of Progressive Disease (PD) after 6 months of the combination of chemotherapy and aflibercept, the patient will be treated with a maintenance therapy with aflibercept alone until PD or unacceptable toxicity, investigator’s decision or patient’s refusal of further treatment or death, whichever comes first.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms,Μεταστατικός Κολοορθικός Καρκίνος

PROVIDER: 2165895 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2013-09-01 | E-GEOD-50519 | biostudies-arrayexpress
| 2254063 | ecrin-mdr-crc
| 2536279 | ecrin-mdr-crc
2022-09-16 | GSE207974 | GEO
2017-08-17 | GSE72969 | GEO
2017-08-17 | GSE72968 | GEO
| 2615831 | ecrin-mdr-crc
| PRJNA996913 | ENA
2016-05-18 | GSE81527 | GEO
| 2288704 | ecrin-mdr-crc